Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-831 adjunctive treatment for negative symptoms of schizophrenia
2017-003471-54Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of luvadaxistat in schizophrenia (4 arms), sponsored by Takeda. Primary endpoint: Change from baseline on the PANSS NSFS. Started Jan 2018; status: completed.
02
Drugs
luvadaxistat
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-003471-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003471-54.